Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 12;9:627. doi: 10.3389/fimmu.2018.00627

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Martínez-Florensa, Català, Velasco-de Andrés, Cañadas, Fraile-Ágreda, Casadó-Llombart, Armiger-Borràs, Consuegra-Fernández, Casals and Lozano.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Additive effects of combined administration of CD6.PD3 and Imipenem/Cilastatin on mouse survival following cecal ligation and puncture (CLP)-induced sepsis. C57BL/6J mice were therapeutically infused 1 h post CLP with saline (n = 31), CD6.PD3 (6 mg/kg intravenous; n = 25), Imipenem/Cilastatin (I/C, 50 mg/kg/12h intraperitoneal; n = 9), or a combination of the two later (n = 11). The average percent survival was analyzed over time for each group and compared to the I/C plus CD6.PD3 group using the long-rank t-test (*P < 0.05 and **P < 0.01).